Key Takeaways
- Approximately 86 million U.S. adults have total cholesterol above 200 mg/dL, making elevated cholesterol one of the most prevalent — and most modifiable — cardiovascular risk factors.[2]
- The 2026 ACC/AHA Dyslipidemia Guideline reintroduces specific LDL-C treatment targets: <100 mg/dL for borderline/intermediate risk, <70 mg/dL for high risk, and <55 mg/dL for very high-risk patients with established cardiovascular disease.[1]
- Statins remain the pillar of lipid-lowering therapy. A 2026 meta-analysis found that only 4 of 66 commonly reported statin side effects are actually caused by the drug — most muscle symptoms are attributable to the nocebo effect.[5]
- Beyond statins, newer options including ezetimibe, PCSK9 inhibitors (evolocumab, alirocumab), inclisiran (twice-yearly injection), and bempedoic acid now give physicians a full toolkit to reach even the most aggressive LDL targets.[6]
- Lifestyle modifications — dietary changes, exercise, and weight management — can reduce LDL by 20–30% when applied aggressively, and remain the foundation of cholesterol management for every patient.[7]
Cholesterol is one of those topics where nearly everyone has heard the basics — "keep your numbers low," "avoid fried food," "take your statin" — but very few patients understand the nuances that actually determine cardiovascular risk. In my practice, I see this knowledge gap every day. A patient's LDL is 145 mg/dL, and they've been told it's "a little high." But is it? The answer depends entirely on their individual risk profile, and the 2026 ACC/AHA guidelines have fundamentally changed how we assess that risk.[1]
The numbers are staggering. Approximately 86 million U.S. adults age 20 and older have total cholesterol levels above 200 mg/dL, and nearly 25 million have levels above 240 mg/dL.[2] A CDC analysis published in March 2026 found that the prevalence of self-reported high cholesterol increased by 13.7% between 2019 and 2023 — a trajectory that shows no signs of slowing.[2] Elevated LDL cholesterol remains the single most important modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), which is the leading cause of death globally.
This guide is designed to give you the same depth of information I would share with a colleague's family member: a thorough, honest overview of what your lipid panel means, when medication is truly necessary, what the latest evidence says about statins and newer drugs, and how to make lifestyle changes that actually move the needle. Whether you are managing an existing prescription refill or trying to understand a new diagnosis, this is your comprehensive reference.
Understanding Your Lipid Panel
A standard lipid panel — usually drawn as a fasting blood test — measures four key values. Each tells a different part of the story, and understanding them individually is the first step toward understanding your cardiovascular risk.
LDL Cholesterol ("Bad Cholesterol")
Low-density lipoprotein (LDL) is the primary driver of atherosclerosis — the process by which cholesterol-rich plaque builds up inside artery walls. LDL particles infiltrate the arterial lining, trigger inflammation, and progressively narrow blood vessels. This amounts to why LDL is the primary target of therapy in every major guideline.[1]
| Risk Category | LDL-C Goal (2026 ACC/AHA) | Who Falls in This Category |
|---|---|---|
| Low risk | Lifestyle counseling; statin if LDL 160–189 mg/dL with elevated 30-year risk | 10-year PREVENT-ASCVD risk <3% |
| Borderline risk | <100 mg/dL | 10-year risk 3% to <5% |
| Intermediate risk | <100 mg/dL | 10-year risk 5% to <10% |
| High risk | <70 mg/dL | 10-year risk ≥10%, or established ASCVD |
| Very high risk | <55 mg/dL | ASCVD with ≥2 major events, or 1 event plus ≥2 high-risk conditions; CAC ≥1,000 |
HDL Cholesterol ("Good Cholesterol")
High-density lipoprotein (HDL) performs the opposite function: it picks up excess cholesterol from arteries and transports it back to the liver for disposal — a process called reverse cholesterol transport. Generally, higher is better: levels below 40 mg/dL in men or 50 mg/dL in women are considered a risk factor. However, the relationship isn't linear — pharmacologically raising HDL has not been shown to reduce cardiovascular events, which is why current guidelines focus on lowering LDL rather than raising HDL.[4]
Triglycerides
Triglycerides are a type of fat in the blood that the body uses for energy. Normal levels are below 150 mg/dL. Elevated triglycerides (especially above 200 mg/dL) are associated with increased cardiovascular risk and are often linked to metabolic syndrome, diabetes, obesity, and excess alcohol intake. Very high levels (above 500 mg/dL) carry a risk of acute pancreatitis and require urgent treatment.
Total Cholesterol
Total cholesterol is the sum of LDL, HDL, and 20% of triglycerides. While it provides a general snapshot, it can be misleading — a patient with a high total cholesterol driven by a very high HDL is in a different situation than one with a high total cholesterol driven by elevated LDL. It's why we focus on the individual components, particularly LDL-C, when making treatment decisions.
The 2026 ACC/AHA guidelines now include a Class 1 recommendation to measure lipoprotein(a) — Lp(a) — at least once in every adult's lifetime. Elevated Lp(a) (≥50 mg/dL) is a genetically determined, independent risk factor for ASCVD that is not reflected on a standard lipid panel. If your Lp(a) is elevated, it signals a need for more aggressive LDL lowering and management of other risk factors. Apolipoprotein B (apoB) testing also has a clearer pathway for guiding treatment in the updated guidelines.[1]
Why Cholesterol Matters: Atherosclerosis and Cardiovascular Risk
To understand why we treat cholesterol so aggressively, you need to understand what happens inside your arteries over decades of exposure to elevated LDL.
Atherosclerosis begins when LDL particles penetrate the inner lining (endothelium) of an artery and become oxidized. This triggers an inflammatory cascade: white blood cells migrate to the area, engulf the oxidized LDL, and transform into foam cells. Over time, these foam cells accumulate into fatty streaks, then into fibrous plaques with a lipid-rich core covered by a thin fibrous cap. This process begins silently — often in adolescence — and progresses for decades before producing symptoms.
The danger isn't gradual narrowing alone. The most life-threatening event occurs when a vulnerable plaque ruptures, exposing its contents to the bloodstream and triggering a blood clot (thrombus) that can suddenly and completely block the artery. This represents the mechanism behind most heart attacks and many strokes. A coronary artery that was only 40% narrowed yesterday can be 100% occluded today if the plaque ruptures.
This is why the concept of cumulative LDL exposure is central to the 2026 guidelines. It's not just your LDL level today that matters — it's the total amount of LDL your arteries have been exposed to over your lifetime. As Roger Blumenthal, MD, chair of the 2026 guideline writing committee, stated: "Lower LDL for longer, just like lower blood pressure for longer, results in much greater protection against future heart attack and stroke risk."[1] This principle drives the guideline's emphasis on earlier intervention.
What's New: The 2026 ACC/AHA Dyslipidemia Guideline
Published on March 13, 2026, the new ACC/AHA guideline represents the most significant update to U.S. cholesterol management in eight years. It replaces the 2018 guideline and consolidates recommendations for LDL cholesterol, triglycerides, and lipoprotein(a) into a single comprehensive document.[1] Here are the changes that matter most for patients:
The 2013 and 2018 U.S. guidelines controversially eliminated specific LDL-C treatment targets, recommending instead that physicians prescribe a certain intensity of statin without aiming for a number. The 2026 guideline reverses this, reintroducing concrete LDL-C goals: <100 mg/dL for borderline/intermediate risk, <70 mg/dL for high risk, and <55 mg/dL for very high-risk secondary prevention patients. This aligns the U.S. with European Society of Cardiology guidelines and reflects the consistent trial data showing that lower LDL levels produce greater cardiovascular benefit.[1]
The older Pooled Cohort Equations, which overestimated 10-year risk by 40–50% in many populations, have been replaced by the PREVENT-ASCVD equations for adults ages 30–79 without known ASCVD. The new calculator classifies 10-year risk as low (<3%), borderline (3% to <5%), intermediate (5% to <10%), or high (≥10%), and can also estimate 30-year risk to guide earlier intervention in younger patients. The new risk categories use health information already obtained during an annual physical — cholesterol, blood pressure, age, and health habits — with optional "risk enhancers" such as family history, South Asian or Filipino ancestry, elevated Lp(a), coronary artery calcium (CAC) score, and inflammatory conditions.[1]
Other Key Updates
- Coronary artery calcium (CAC) scoring now has a stronger role: CAC ≥100 triggers an LDL goal of <70 mg/dL, and CAC ≥1,000 triggers a goal of <55 mg/dL — the same as very high-risk ASCVD patients.
- Earlier pharmacotherapy is recommended: the guideline considers statin therapy reasonable even at borderline risk (10-year PREVENT-ASCVD 3% to <5%), a significant shift from prior practice.
- New drugs are incorporated: bempedoic acid (Nexletol), inclisiran (Leqvio), and evinacumab (Evkeeza) — all approved since 2018 — are now part of the treatment algorithm.
- Special populations receive focused attention: statin initiation is recommended for adults ≥40 with chronic kidney disease (stage 3+), HIV, or Type 1 or Type 2 diabetes.
Statin Therapy: How They Work, Intensity Levels, and Side Effects
Statins have been the backbone of cardiovascular prevention for over three decades. They are among the most extensively studied drugs in the history of medicine, with data from hundreds of thousands of patients across randomized controlled trials demonstrating consistent, significant reductions in heart attacks, strokes, and cardiovascular death.
How Statins Work
Statins inhibit HMG-CoA reductase, an enzyme in the liver that is essential for cholesterol synthesis. By blocking this enzyme, statins reduce the liver's production of cholesterol, which triggers the liver to increase the number of LDL receptors on its surface. These receptors pull LDL out of the bloodstream, lowering circulating LDL-C levels. Beyond lipid lowering, statins also have anti-inflammatory effects, stabilize existing plaques, and improve endothelial function.
Statin Intensity Levels
| Intensity | Expected LDL Reduction | Examples |
|---|---|---|
| High-intensity | ≥50% | Atorvastatin 40–80 mg; Rosuvastatin 20–40 mg |
| Moderate-intensity | 30–49% | Atorvastatin 10–20 mg; Rosuvastatin 5–10 mg; Simvastatin 20–40 mg; Pravastatin 40–80 mg |
| Low-intensity | <30% | Simvastatin 10 mg; Pravastatin 10–20 mg; Lovastatin 20 mg |
The 2026 guidelines recommend high-intensity statins (targeting ≥50% LDL reduction) for patients at high or very high cardiovascular risk, and moderate-intensity statins for those at borderline or intermediate risk.[1]
Separating Real Side Effects from the Nocebo Effect
If there is one myth I spend more time addressing than any other in my practice, it is the belief that statins routinely cause debilitating muscle pain. Let me be direct about what the evidence shows.
A landmark 2026 meta-analysis of 19 placebo-controlled trials, encompassing over 120,000 participants, found that only 4 of the 66 side effects listed on statin package inserts are actually caused by statins themselves, and even those occur at very low rates.[5] The researchers concluded that the current list of side effects on statin labels should be revised to better reflect the evidence.
The SAMSON and StatinWISE trials — personalized N-of-1 studies where individual patients were randomized to multiple periods of statin, placebo, and no tablet — demonstrated that patients reported nearly identical symptom burdens on statin and placebo. The difference between the two was statistically insignificant. What was significant was the difference between taking any tablet (statin or placebo) and taking nothing — confirming a powerful nocebo effect, where the expectation of side effects causes real symptoms.[5]
Perhaps most importantly, up to 50% of patients who believed they were statin-intolerant were able to successfully restart statins after participating in these blinded trials. This is one of the most impactful findings in preventive cardiology in recent years. If you have stopped a statin due to muscle symptoms, I strongly encourage you to discuss a rechallenge with your physician — potentially with a different statin, a lower dose, or an alternate-day regimen.
That said, true statin-related myopathy does exist, albeit rarely. The risk of clinically significant muscle injury (rhabdomyolysis) is approximately 1 in 10,000 patient-years. Risk factors include older age, small body frame, hypothyroidism, kidney disease, and drug interactions — particularly with gemfibrozil, certain antifungals, and some immunosuppressants. If you develop unexplained severe muscle pain, weakness, or dark-colored urine while on a statin, seek medical evaluation promptly.
Beyond Statins: The Expanding Cholesterol Medication Toolkit
Statins alone are insufficient for many patients — particularly those with familial hypercholesterolemia, statin intolerance, or very high-risk ASCVD requiring LDL levels below 55 mg/dL. The treatment environment has expanded dramatically since the 2018 guidelines, and the 2026 update incorporates several newer agents.
Ezetimibe (Zetia)
How it works: Blocks cholesterol absorption in the small intestine, reducing the amount of cholesterol delivered to the liver. This complements statins, which reduce cholesterol production.
Efficacy: Reduces LDL by an additional 15–25% when added to a statin. It is the recommended first add-on therapy when statins alone don't achieve the LDL target.
Practical notes: Oral, once-daily, well-tolerated, inexpensive (now generic). Very few side effects. In my practice, ezetimibe is the workhorse second-line agent.
PCSK9 Inhibitors: Evolocumab (Repatha) and Alirocumab (Praluent)
How they work: These monoclonal antibodies block PCSK9, a protein that degrades LDL receptors on the liver surface. By inhibiting PCSK9, more LDL receptors remain active, pulling more LDL out of the blood.
Efficacy: Reduce LDL by up to 60% on top of statin therapy. The FOURIER trial (evolocumab) and ODYSSEY OUTCOMES trial (alirocumab) both demonstrated significant reductions in cardiovascular events.
Key 2025 update: In August 2025, the FDA broadened the indication for evolocumab (Repatha) to include adults at increased risk for major cardiovascular events due to uncontrolled LDL-C, removing the prior requirement for an existing cardiovascular disease diagnosis. This expands access to primary prevention patients who cannot reach LDL goals with statins and ezetimibe alone.[6]
Practical notes: Self-administered subcutaneous injection every 2 weeks or monthly. Cost has decreased significantly; many patients now qualify for insurance coverage or manufacturer assistance programs.
Inclisiran (Leqvio)
How it works: A small interfering RNA (siRNA) that silences the gene responsible for producing PCSK9 in the liver. Rather than blocking the protein after it's made (like evolocumab/alirocumab), inclisiran prevents the protein from being produced in the first place.
Efficacy: Reduces LDL by approximately 50%, with the effect sustained over the full dosing interval.
Key 2025 update: In July 2025, the FDA approved inclisiran as a first-line monotherapy option alongside diet and exercise for adults with hypercholesterolemia — removing the prior requirement that it be used only on top of statin therapy. This makes it available much earlier in the treatment pathway.[6]
Practical notes: The major advantage is dosing: a healthcare provider administers the injection at Day 1, Day 90, and then every 6 months thereafter. For patients who struggle with daily pills or biweekly injections, twice-yearly dosing can dramatically improve adherence.
Bempedoic Acid (Nexletol)
How it works: Inhibits ATP citrate lyase (ACL), an enzyme upstream of HMG-CoA reductase in the cholesterol synthesis pathway. Worth stressing: bempedoic acid is a prodrug that is activated only in the liver — not in skeletal muscle — which is why it does not cause the muscle symptoms associated with statins.
Efficacy: The CLEAR Outcomes trial demonstrated that bempedoic acid reduces LDL by 21.1%, hsCRP by 22.2%, and the risk of major cardiovascular events (MACE-4) by 13% in patients who are unable or unwilling to take guideline-recommended statin doses.[3]
Practical notes: Oral, once-daily. Particularly valuable for statin-intolerant patients. Side effects include small increases in gout and gallstones. Available as a single agent or in combination with ezetimibe (Nexlizet).
Icosapent Ethyl (Vascepa) — For Elevated Triglycerides
How it works: A purified form of the omega-3 fatty acid EPA. Unlike fish oil supplements, icosapent ethyl does not raise LDL cholesterol.
Efficacy: The REDUCE-IT trial showed that 4 g/day of icosapent ethyl reduced the risk of major cardiovascular events by 25% in statin-treated patients with elevated triglycerides (135–499 mg/dL) and established ASCVD or diabetes.
Practical notes: This is not a general triglyceride-lowering supplement — it is a targeted therapy for patients with persistent hypertriglyceridemia despite statin therapy who are at high cardiovascular risk. Standard fish oil supplements have not shown the same cardiovascular benefit.
Decision Framework: Routine Refill, Talk to Your Doctor, or Seek Emergency Care
One of the most practical things I can offer is a framework for when you need action — and what kind. Here is how I guide my patients:
| Scenario | Recommended Action | Rationale |
|---|---|---|
| Stable on current statin/cholesterol medication with LDL at goal, no new symptoms, due for refill | ✅ Routine refill — continue current therapy | Consistent adherence is the single most important factor in long-term cardiovascular risk reduction. Do not stop or change medication without physician guidance. |
| Mild muscle aches after starting or changing a statin; no weakness, no dark urine | 📋 Schedule a conversation with your doctor within 1–2 weeks | Most muscle complaints are nocebo-related and can be addressed with reassurance, switching to a different statin, dose adjustment, or alternate-day dosing. Do not stop the statin without medical advice. |
| LDL not at goal despite current therapy; risk factors present (diabetes, family history, smoking) | 📋 Discuss intensifying therapy at your next appointment | Options include increasing statin intensity, adding ezetimibe, or considering a PCSK9 inhibitor or inclisiran. The 2026 guidelines support treat-to-target approaches. |
| New diagnosis of very high triglycerides (>500 mg/dL) | ⚠️ Contact your physician promptly (same week) | Triglycerides above 500 mg/dL carry a significant risk of acute pancreatitis. Dietary restriction and possibly fibrates or icosapent ethyl are needed urgently. |
| Severe muscle pain with weakness, dark or tea-colored urine, fever — while on a statin | 🚨 Seek emergency care immediately | These may indicate rhabdomyolysis — a rare but serious breakdown of muscle tissue that can cause kidney failure. This requires emergency evaluation, blood tests (CK, renal function), and immediate statin discontinuation. |
| Chest pain, sudden weakness on one side, difficulty speaking, or severe headache | 🚨 Call 911 immediately | These are signs of a heart attack or stroke — the very events that cholesterol management aims to prevent. Every minute matters. Do not drive yourself to the hospital. |
Lifestyle Modifications: What Actually Moves the Numbers
Every patient I treat for cholesterol hears the same message: medication works best when it's built on a foundation of healthy habits. Lifestyle modifications are never "instead of" medication for patients at significant risk — but they are always "in addition to" it, and in lower-risk patients, they may be sufficient on their own. Here's what the evidence supports, with quantified expectations:[7]
Dietary Modifications
- Reduce saturated fat to <7% of daily calories (replacing with unsaturated fats): lowers LDL by 8–10%
- Increase soluble fiber to 10–25 g/day (oatmeal, beans, barley, apples, citrus): lowers LDL by 3–5% per 5–10 g added
- Add plant stanols/sterols (2 g/day, available in fortified foods and supplements): lowers LDL by 6–15%
- Adopt a Mediterranean or Portfolio Diet pattern: combined LDL reduction of 20–30% — approaching moderate-intensity statin territory
- Eliminate trans fats completely: even small amounts raise LDL and lower HDL
Physical Activity
- 150 minutes/week of moderate aerobic exercise (brisk walking, cycling, swimming): raises HDL by 5–10%, lowers triglycerides by 10–20%, modestly reduces LDL
- Vigorous exercise (running, HIIT): more pronounced effects on triglycerides and HDL
- Even short daily walks provide benefit — any movement is better than none
Weight Management
- Losing 10% of body weight can reduce LDL by 5–8%, triglycerides by 20–30%, and increase HDL by 5–10%
- Weight loss also improves insulin sensitivity, blood pressure, and inflammation — compounding cardiovascular benefit beyond the lipid panel
Smoking Cessation
- Quitting smoking raises HDL by 5–10% within weeks and reduces cardiovascular risk by approximately 50% within one year
- Smoking accelerates atherosclerosis through endothelial damage, oxidative stress, and inflammation — independent of its effect on lipids
Patients frequently ask about red yeast rice, garlic, niacin supplements, and general fish oil for cholesterol. Let me be straightforward: red yeast rice contains naturally occurring lovastatin and can lower LDL, but product quality is unregulated and some preparations contain a kidney-toxic contaminant (citrinin). Garlic has no meaningful effect on LDL. Over-the-counter fish oil supplements have not been shown to reduce cardiovascular events — only prescription icosapent ethyl (Vascepa) has demonstrated this benefit in trials. Niacin raises HDL but does not reduce cardiovascular events and increases side effects. In general, if a supplement sounds too good to be true for cholesterol, it is.
Red Flags: When to Seek Emergency Care
- Chest pain, pressure, or tightness — especially if radiating to the arm, jaw, or back; may indicate a heart attack
- Sudden weakness or numbness on one side of the body — a hallmark of stroke
- Difficulty speaking or sudden confusion — another stroke warning sign
- Severe, unexplained muscle pain with dark or tea-colored urine — may indicate rhabdomyolysis (rare statin complication requiring emergency treatment)
- Sudden severe abdominal pain with very high triglycerides — may indicate acute pancreatitis
- Severe allergic reaction to any medication (rash, swelling, difficulty breathing)
- Sudden severe headache with no known cause — may indicate hemorrhagic stroke
High cholesterol itself is a "silent" condition — it produces no symptoms until a cardiovascular event occurs. This is precisely what makes it dangerous and why proactive screening, treatment, and adherence matter so much. The symptoms listed above are not from cholesterol itself but from the downstream consequences of untreated or undertreated atherosclerotic disease. By the time symptoms appear, significant damage has already occurred.
Frequently Asked Questions
This is one of the most important questions in cardiovascular medicine. Large placebo-controlled trials — including the SAMSON and StatinWISE studies — showed that patients report nearly identical rates of muscle symptoms on statin and placebo. A 2026 meta-analysis of 19 trials with over 120,000 participants found only 4 of 66 commonly listed statin side effects are actually caused by the drug, at very low rates.[5] The nocebo effect — where the expectation of side effects causes real symptoms — accounts for the majority of reported muscle complaints. Remarkably, up to 50% of patients who believed they were statin-intolerant successfully restarted statins after participating in blinded trials. If you've stopped a statin due to muscle symptoms, consider discussing a rechallenge with your physician.
No — this is a common and potentially dangerous misconception. Your cholesterol is at goal because the statin is working. Statins do not cure the underlying tendency toward high cholesterol; they manage it continuously. If you stop, your LDL will return to its pre-treatment level within weeks, and your cardiovascular risk will increase accordingly. The benefit of statin therapy is cumulative — the longer you maintain low LDL levels, the greater the protection against heart attack and stroke. Never discontinue a statin without discussing it with your physician first.
PCSK9 inhibitors are a class of medications that lower LDL by up to 60% when added to statin therapy. Currently available agents include evolocumab (Repatha), alirocumab (Praluent), and inclisiran (Leqvio). They are typically recommended for patients with established cardiovascular disease or familial hypercholesterolemia who cannot reach their LDL goal despite maximally tolerated statin therapy plus ezetimibe. In 2025, the FDA broadened the indication for evolocumab to include adults at increased cardiovascular risk from uncontrolled LDL-C — even without prior heart attack or stroke — and approved inclisiran for first-line monotherapy use.[6] If your LDL remains above target after optimizing statin and ezetimibe, ask your physician about these options.
Lifestyle modifications can meaningfully reduce LDL: cutting saturated fat lowers LDL by 8–10%, adding 10 g of soluble fiber daily reduces it by another 3–5%, plant stanols/sterols lower it by 6–15%, and an aggressive dietary approach like the Portfolio or Mediterranean diet can reduce LDL by 20–30% combined. Regular exercise (150 minutes/week) primarily raises HDL by 5–10% and improves triglycerides. Losing 10% of body weight reduces LDL by 5–8%.[7] However, for patients at high cardiovascular risk or with very elevated LDL, lifestyle changes alone are typically insufficient and should be combined with medication.
Inclisiran (Leqvio) is a small interfering RNA (siRNA) therapy — a fundamentally different approach. Instead of blocking the PCSK9 protein after it's produced (like Repatha and Praluent), inclisiran silences the gene that makes PCSK9 in the first place. The major advantage is the dosing schedule: just one healthcare-provider injection at Day 1, Day 90, then every 6 months — compared to biweekly or monthly self-injections for traditional PCSK9 inhibitors. It reduces LDL by about 50%. In July 2025, the FDA approved inclisiran as first-line monotherapy alongside diet and exercise, removing the requirement for concurrent statin use.[6]
Genetics play a significant role in cholesterol levels for many patients. Familial hypercholesterolemia (FH) is an inherited condition affecting approximately 1 in 250 people, caused by mutations in genes involved in LDL receptor function. Patients with FH can have LDL levels of 190 mg/dL or higher from childhood, leading to premature heart disease — sometimes as early as the 30s or 40s. The heterozygous form (one affected gene copy) is common; the homozygous form (both copies) is rare but severe. FH is dramatically underdiagnosed — fewer than 10% of affected individuals in the U.S. have been identified. If you have a family history of very high cholesterol or early heart attacks (before age 55 in men or 65 in women), ask your physician about screening for FH. Early, aggressive treatment can be lifesaving.
References
- American College of Cardiology / American Heart Association. 2026 ACC/AHA Guideline for the Management of Patients with Dyslipidemia. Published March 13, 2026. https://www.acc.org/latest-in-cardiology/journal-scans/2026/03/13/15/20/acc-aha-release-new-clinical-guideline-for-managing-dyslipidemia
- Centers for Disease Control and Prevention (CDC). High Cholesterol Facts and Data. Updated October 2024. https://www.cdc.gov/cholesterol/data-research/facts-stats/index.html
- Nicholls SJ, Lincoff AM, Garcia D, et al. Impact of Bempedoic Acid on Total Cardiovascular Events: CLEAR Outcomes Prespecified Analysis. JAMA Cardiology. 2024. https://jamanetwork.com/journals/jamacardiology/fullarticle/2813647
- American Heart Association. About Cholesterol. Updated March 2026. https://www.heart.org/en/health-topics/cholesterol/about-cholesterol
- Howard JP, Wood FA, Finegold JA, et al. Statin Side Effects and the Nocebo Effect: Personalized (N-of-1) Trials (StatinWISE, SAMSON). Harvard Data Science Review. https://pmc.ncbi.nlm.nih.gov/articles/PMC10857873/ | 2026 Lancet meta-analysis via SMC España
- Novartis. Leqvio (inclisiran) Receives FDA Approval for New Indication Enabling First-Line Use. July 31, 2025. https://www.novartis.com/us-en/news/media-releases/novartis-twice-yearly-leqvio-inclisiran-receives-fda-approval-new-indication-enabling-first-line-use | Amgen. Repatha Expanded Indication. August 25, 2025. Amgen Newsroom
- Mayo Clinic. Top 5 Lifestyle Changes to Improve Your Cholesterol. Updated February 2026. https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/reduce-cholesterol/art-20045935